Diabetes, Vol 49, Issue 5 782-788, Copyright © 2000 by American Diabetes Association

ARTICLES

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes

TA Buchanan, AH Xiang, RK Peters, SL Kjos, K Berkowitz, A Marroquin, J Goico, C Ochoa and SP Azen
Department of Medicine, University of Southern California School of Medicine, Los Angeles, USA. buchanan@hsc.usc.edu

The purpose of this study was to examine the response of pancreatic beta-cells to changes in insulin sensitivity in women at high risk for type 2 diabetes. Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12). Insulin sensitivity was assessed by minimal model analysis, and beta-cell insulin release was assessed as acute insulin responses to glucose (AIRg) and tolbutamide (AIRt) during FSIGTs and as the 30-min incremental insulin response (30-min dINS) during OGTTs. Beta-cell compensation for insulin resistance was assessed as the product (disposition index) of minimal model insulin sensitivity and each of the 3 measures of beta-cell insulin release. In the placebo group, there was no significant change in insulin sensitivity or in any measure of insulin release, beta-cell compensation for insulin resistance, or glucose tolerance. Troglitazone treatment resulted in a significant increase in insulin sensitivity, as reported previously. In response, AIRg did not change significantly, so that the disposition index for AIRg increased significantly from baseline (P = 0.004) and compared with placebo (P = 0.02). AIRt (P = 0.001) and 30-min dINS (P = 0.02) fell with improved insulin sensitivity during troglitazone treatment, so that the disposition index for each of these measures of beta-cell function did not change significantly from baseline (P > 0.20) or compared with placebo (P > 0.3). Minimal model analysis revealed that 89% of the change from baseline in insulin sensitivity during troglitazone treatment was accounted for by lowered plasma insulin concentrations. Neither oral nor intravenous glucose tolerance changed significantly from baseline or compared with placebo during troglitazone treatment. The predominant response of beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes was a reduction in insulin release to maintain nearly constant glucose tolerance.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. Ouellet, J. Marois, S. J. Weisnagel, and H. Jacques Dietary Cod Protein Improves Insulin Sensitivity in Insulin-Resistant Men and Women: A randomized controlled trial Diabetes Care, November 1, 2007; 30(11): 2816 - 2821. [Abstract] [Full Text] [PDF]

				T. A. Buchanan, A. Xiang, S. L. Kjos, and R. Watanabe What Is Gestational Diabetes? Diabetes Care, July 1, 2007; 30(Supplement_2): S105 - S111. [Full Text] [PDF]

				R. M. Watanabe, H. Allayee, A. H. Xiang, E. Trigo, J. Hartiala, J. M. Lawrence, and T. A. Buchanan Transcription Factor 7-Like 2 (TCF7L2) Is Associated With Gestational Diabetes Mellitus and Interacts With Adiposity to Alter Insulin Secretion in Mexican Americans Diabetes, May 1, 2007; 56(5): 1481 - 1485. [Abstract] [Full Text] [PDF]

				S. Lim, S. H. Choi, Y. J. Park, K. S. Park, H. K. Lee, H. C. Jang, N. H. Cho, and B. E. Metzger Visceral Fatness and Insulin Sensitivity in Women With a Previous History of Gestational Diabetes Mellitus Diabetes Care, February 1, 2007; 30(2): 348 - 353. [Abstract] [Full Text] [PDF]

				J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]

				N. Rasouli, P. A Kern, E. A. Reece, and S. C. Elbein Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E359 - E365. [Abstract] [Full Text] [PDF]

				A. H. Xiang, C. Wang, R. K. Peters, E. Trigo, S. L. Kjos, and T. A. Buchanan Coordinate Changes in Plasma Glucose and Pancreatic {beta}-Cell Function in Latino Women at High Risk for Type 2 Diabetes. Diabetes, April 1, 2006; 55(4): 1074 - 1079. [Abstract] [Full Text] [PDF]

				A. M. Chang, M. J. Smith, C. J. Bloem, A. T. Galecki, J. B. Halter, and M. A. Supiano Limitation of the Homeostasis Model Assessment to Predict Insulin Resistance and {beta}-Cell Dysfunction in Older People J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 629 - 634. [Abstract] [Full Text] [PDF]

				J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan, and R. M. Watanabe Sequence Variation in PPARG May Underlie Differential Response to Troglitazone Diabetes, November 1, 2005; 54(11): 3319 - 3325. [Abstract] [Full Text] [PDF]

				S. H. Kim, F. Abbasi, J. W. Chu, T. L. McLaughlin, C. Lamendola, K. S. Polonsky, and G. M. Reaven Rosiglitazone Reduces Glucose-Stimulated Insulin Secretion Rate and Increases Insulin Clearance in Nondiabetic, Insulin-Resistant Individuals Diabetes, August 1, 2005; 54(8): 2447 - 2452. [Abstract] [Full Text] [PDF]

				A. H. Xiang, R. K. Peters, S. L. Kjos, C. Ochoa, A. Marroquin, J. Goico, S. Tan, C. Wang, S. P. Azen, C.-r. Liu, et al. Effect of Thiazolidinedione Treatment on Progression of Subclinical Atherosclerosis in Premenopausal Women at High Risk for Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1986 - 1991. [Abstract] [Full Text] [PDF]

				J.-L. Chiasson and R. Rabasa-Lhoret Prevention of Type 2 Diabetes: Insulin Resistance and Beta-Cell Function Diabetes, December 1, 2004; 53(suppl_3): S34 - S38. [Abstract] [Full Text] [PDF]

				S. Snitker, R. M. Watanabe, I. Ani, A. H. Xiang, A. Marroquin, C. Ochoa, J. Goico, A. R. Shuldiner, and T. A. Buchanan Changes in Insulin Sensitivity in Response to Troglitazone Do Not Differ Between Subjects With and Without the Common, Functional Pro12Ala Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene Variant: Results from the Troglitazone in Prevention of Diabetes (TRIPOD) study Diabetes Care, June 1, 2004; 27(6): 1365 - 1368. [Abstract] [Full Text] [PDF]

				R. Lupi, S. Del Guerra, L. Marselli, M. Bugliani, U. Boggi, F. Mosca, P. Marchetti, and S. Del Prato Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPAR{gamma}2 in the modulation of insulin secretion Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E560 - E567. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, G. Penarroja, C. Richart, A. Castro, J. Vendrell, M. Broch, A. Lopez-Bermejo, and W. Ricart G Protein {beta}3 Gene Variant, Vascular Function, and Insulin Sensitivity in Type 2 Diabetes Hypertension, January 1, 2003; 41(1): 124 - 129. [Abstract] [Full Text] [PDF]

				T. A. Buchanan, A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H. N. Hodis, et al. Preservation of Pancreatic {beta}-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women Diabetes, September 1, 2002; 51(9): 2796 - 2803. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, G. Penarroja, A. Castro, F. Garcia-Bragado, I. Hernandez-Aguado, and W. Ricart Blood Letting in High-Ferritin Type 2 Diabetes : Effects on Insulin Sensitivity and {beta}-Cell Function Diabetes, April 1, 2002; 51(4): 1000 - 1004. [Abstract] [Full Text] [PDF]

				R. N. Bergman, M. Ader, K. Huecking, and G. Van Citters Accurate Assessment of {beta}-Cell Function: The Hyperbolic Correction Diabetes, February 1, 2002; 51(90001): S212 - 220. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				T. A. Buchanan Pancreatic B-Cell Defects in Gestational Diabetes: Implications for the Pathogenesis and Prevention of Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 989 - 993. [Full Text]